The vaccine was able to break tolerance to the self-antigen and produced specific antibodies against mouse PAMP, reduced tumor angiogenesis and tumor cell proliferation, and elevated levels of CD8+ T cells, but unfortunately, it was not able to reduce tumor burden. This evidence concerns the gene CD8A and neoplasm.